BioSpace News Archive

Fact MR, Dubai: Rising prevalence of ovarian cancer in women is creating demand for cancer antigen tests.

Genuity Science, a genomics data, analytics and insights organization, announced its participation with leading life science technology company, 10x Genomics through 10x Genomics’ Certified Service Provider program.

InnoCare Pharma, a leading biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its Bruton’s tyrosine kinase inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Incisive Genetics Inc., a privately held biotech company specializing in non-viral delivery methods for targeted gene therapies, announced the formation of its Scientific Advisory Board and the appointment of Dr. Michael R. Hayden as chairperson.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.

Clovis Oncology, Inc., announced that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals, published a retrospective report of their independent experience with FAP-2286 in named-patient use in The Journal of Nuclear Medicine.

Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced the appointment of Manjunath Ramarao, Ph.D., as senior vice president in its research and development team.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, announced the appointment of Paul Brannelly as Chief Financial Officer.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced it has signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats.

Mosaic ImmunoEngineering Inc. announced today that it has submitted its initial application to list the company’s common stock on the Nasdaq Capital Market.